Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi. Pipeline Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments for dermatological diseases based on […]
